VA-REGULA
25.7.2024 08:01:30 CEST | Business Wire | Press release
Regula, a global developer of forensic devices and identity verification solutions, prepared a dedicated package of expert articles focused on document verification, tailored to meet the needs of carriers, border verification authorities, the hospitality industry, and businesses during the 2024 Olympics. These resources aim to address the unique challenges posed by the influx of international visitors, ensuring seamless and secure experiences for all.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724663488/en/
Effective Identity Verification for the Olympics 2024: how is it done? Regula's vision (Graphic: Regula)
France anticipates a significant boost in tourism and economic activity during the 2024 Olympics, with over 10 million visitors projected to generate an estimated €3 billion in revenue. This massive surge in visitors will not only increase the risk of fraud targeting consumers and businesses but also pose substantial challenges for security and access management. The influx of international guests underscores the critical need for advanced and comprehensive Identity Verification (IDV) systems.
Properly verifying and authorizing everyone at every stage of their Olympic journey is essential for maintaining security and ensuring smooth access to event venues and services.
1. Addressing Carrier Requirements for Advance Passenger Information
With recent EU regulations mandating the collection of advance passenger information, carriers face unprecedented challenges. Our topic, "How Carriers Can Tackle New Requirements for Gathering Advance Passenger Information," provides comprehensive insights and practical solutions to help carriers comply with these regulations efficiently. As the Olympics are hosted in France, this information is crucial for ensuring smooth travel experiences for millions of visitors.
2. Professional Border Verification Techniques
Border control is a critical component of international events. Our resources include:
- "How to Verify a Passport Like a Pro": A detailed guide on the best practices for passport verification.
- "How Regula Creates the Most Full and Detailed Document Reference System": An in-depth look at how Regula's advanced technology supports border control authorities with the most comprehensive document reference systems available. It contains templates of passports, ID cards, visas, banknotes, coins, driver’s licenses, and vehicle documents from all over the world.
- To gain a better understanding of the verification tools needed, from border controls to customer authorization by businesses, check the article “Regula ID Document Templates Database vs. Information Reference System”.
These topics are designed to empower border officials with the knowledge and tools needed to maintain security while facilitating the flow of visitors.
3. Transforming Travel & Hospitality with Data Entry Automation
In the hospitality sector, efficient check-ins are vital for a positive guest experience. At the same time, manual entry of ID details in hotels can often cause long lines, messes, and delays.
Our topic, "How Data Entry Automation Transforms Travel & Hospitality," highlights the latest innovations in reader technology and software. It provides examples of automated check-in processes and calls to action for hospitality businesses to leverage these advancements for a competitive edge.
4. Solving Business Challenges of Foreign Documents Verification
Businesses are facing an increase in the number of international customers, and the smart ones start adapting to the challenges of verifying foreign documents. Our article, "Foreign ID Document Verification for Businesses,” offers practical advice and solutions for businesses to navigate these complexities, ensuring they can confidently verify the identities of international customers.
To get access to all the expert articles in one place, visit the landing page “Securing the Olympics 2024”.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724663488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom